COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
06/05/2026
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s [...]
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
06/05/2026
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue [...]
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
06/05/2026
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced the pricing of a [...]
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
06/05/2026
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and [...]
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
06/05/2026
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
06/05/2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
06/05/2026
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United [...]
Recursion Reports First Quarter Financial Results and Provides Business Update
06/05/2026
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose- [...]
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
06/05/2026
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company [...]
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
06/05/2026
Lyon (France), May 6 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The [...]
Valneva publiera ses résultats financiers consolidés du premier trimestre le 13 mai 2026
06/05/2026
Lyon (France), le 6 mai 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier trimestre le mercredi 13 [...]
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
06/05/2026
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
06/05/2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Glass House Brands Announces Application for DEA Registration of Certain Medical Operations
06/05/2026
LONG BEACH, Calif. and TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced that it has submitted [...]
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX ® , its latest innovation in its popular line- [...]
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
06/05/2026
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell’s next generation personalized immunotherapy [...]
Bioventus Reports First Quarter Financial Results
06/05/2026
Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share [...]
Medline Reports First Quarter 2026 Results
06/05/2026
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5 [...]

Pages